US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Beta Bionic Inc (BBNX): Bullish IPO Roadshow Moves Underwriters to Amend Offering Size and Range

Beta Bionic Inc (BBNX): IPO Pops, Trades Strong on Opening Day

Beta Bionic Inc (BBNX) Six Month Summary: From Breakout to Breakdown

Beta Bionic, Inc. (BBNX): IPO Terms Set for Medical Device Company Aiding Insulin Patients

Beta Bionic, Inc. (BBNX) - Medical Device Company Targeting the Insulin Market Prepares for Q1 IPO

Beta Bionics IPO: Will The Innovative MedTech Company Repeat The Success of Livongo Health?

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>The company has jumped from just eight sales territories in Q2 2023 to 43 sales to end 2024 with more than 15,000 units installed.</li>
<li>An existing shareholder is on the cover of the prospectus with a concurrent private placement</li>
<li>Medical Device IPOs have a strong history of success as many are poised for growth</li>
</ul>


The company has jumped from just eight sales territories in Q2 2023 to 43 sales to end 2024 with more than 15,000 units installed.
An existing shareholder is on the cover of the prospectus with a concurrent private placement
Medical Device IPOs have a strong history of success as many are poised for growth


Beta Bionic, Inc. (BBNX): IPO Is An "Execution Story" And in Growth Mode